Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

NCT01500083 is registered in ClinicalTrials.gov with Lundbeck Canada Inc. as lead sponsor.

NCT NCT01500083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01500083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Expanded Access Trial for Bendamustine HCl in Patients With Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Lead sponsor
Lundbeck Canada Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2012
Completion date
June 30, 2013
Enrollment
90 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, indolent non-hodgkin's lymphoma